The underuse of digoxin in heart failure, and approaches to appropriate use

Most of the estimated 400 000 Canadians who experience heart failure are 65 years of age or older. Heart failure is the most frequent reason for hospital admission for older adults. Admission for heart failure is a marker of disease progression, a cause of poor quality of life and a burden to the

[1]  Ali Ahmed,et al.  Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.

[2]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[3]  Luigi Tavazzi,et al.  Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.

[4]  M. Gheorghiade,et al.  Digoxin in the management of cardiovascular disorders. , 2004, Circulation.

[5]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[6]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[7]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[8]  J. H. Patterson,et al.  Clinical benefits of low serum digoxin concentrations in heart failure. , 2002, Journal of the American College of Cardiology.

[9]  P. Grayburn,et al.  Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? , 1997, Journal of the American College of Cardiology.

[10]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[11]  M. Rich,et al.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. , 2006, European heart journal.

[12]  R. McKelvie,et al.  Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. , 2006, The Canadian journal of cardiology.

[13]  J. Brophy.  Rehabilitating digoxin. , 2006, European heart journal.

[14]  J. Brophy.  Rehabilitating digoxinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. , 2006 .